The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1
Open accessPublished version of a preprint
Abstract
Checkpoints are present in all phases of the cell cycle and are regarded as the gatekeepers maintaining the integrity of the genome. Many conventional agents used to treat cancer impart damage to the genome and activate cell cycle checkpoints. Many tumors are defective in the tumor suppressor p53 and therefore lack a functional G1 checkpoint. In these tumors, however, the S-G2 checkpoints remain intact and, in response to DNA damage, arrest cell cycle progression allowing time for DNA repair. Checkpoint kinase 1 (Chk1) is a key element in the DNA damage response pathway and plays a crucial role in the S-G2-phase checkpoints. Inhibiting Chk1 represents a therapeutic strategy for creating a “synthetic lethal” response by overriding the last checkpoint defense of tumor cells against the lethal damage induced by DNA-directed chemotherapeutic agents. Chk1 inhibition is consistent with emerging targeted therapies aiming to exploit molecular differences between normal and cancer cells. Adding a Chk1 inhibitor to DNA-damaging cytotoxic therapy selectively targets tumors with intrinsic checkpoint defects while minimizing toxicity in checkpoint-competent normal cells. PF-00477736 was identified as a potent, selective ATP-competitive small-molecule inhibitor that inhibits Chk1 with a Ki of 0.49 nM. PF-00477736 abrogates cell cycle arrest induced by DNA damage and enhances cytotoxicity of clinically important chemotherapeutic agents, including gemcitabine and carboplatin. In xenografts, PF-00477736 enhanced the antitumor activity of gemcitabine in a dose-dependent manner. PF-00477736 combinations were well tolerated with no exacerbation of side effects commonly associated with cytotoxic agents. [Mol Cancer Ther 2008;7(8):2394–404]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The DNA damage response: putting checkpoints in perspective
Zhou, B.-B. S., & Elledge, S. J. (2000) · Nature · doi:10.1038/35044005 · Cited by 3,213
Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., & Elledge, S. J. (1997) · Science · doi:10.1126/science.277.5331.1497 · Cited by 1,320
Signaling to Chromatin through Histone Modifications
Cheung, P., Allis, C. D., & Sassone-Corsi, P. (2000) · Cell · doi:10.1016/s0092-8674(00)00118-5 · Cited by 989
Research works printed but not linked: 20
- O’Connor PM. Mammalian G1 and G2 phase checkpoints. Cancer Surveys 1997;29:151–82.
- Chen P, Luo C, Dend Y, et al. Implications for Chk1 regulation: the 1.7 Å crystal structure of human cell cycle checkpoint kinase Chk1. Cell 2000;100:681–92. · DOI · Paper page
- Walworth N. Cell-cycle checkpoint kinases: checking in on the cell cycle. Curr Opin Cell Biol 2000;12:697–704. · DOI
- Elledge SJ. Cell Cycle Checkpoints: preventing an identity crisis. Science 1996;274:1664–70. · DOI · Paper page
- Liu Q, Guntuku S, Cui XS, et al. Chk1 is an essential kinase that is regulated by ATR and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000;14:1448–59. · DOI · Paper page
- Luo Y, Leverson JD. New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response. Future Drugs 2005;5:333–42. · DOI
- Powell S, DeFrank J, Connell P, et al. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res 1995;55:1643–8. · DOI · Paper page
- Koniaras K, Cuddihy A, Christopoulos H, Hogg A, O’Connell M. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 2001;20:7453–63. · DOI · Paper page
- Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004;4:213–25. · DOI · Paper page
- Tao ZF, Lin NH. Chk1 inhibitors for novel cancer treatment. Anti Cancer Agents Med Chem 2006;6:377–88. · DOI
- Braakhuis BJ, Ruiz van Harperen VW, Boven E, et al. Schedule-dependent antitumor effect of gemcitabine in in vivo model systems. Semin Oncol 1995;22:42–6.
- Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63. · DOI · Paper page
- Blasina A, Paegle ES, McGowan CH. The role of inhibitory phosphorylation of CDC2 following DNA replication block and radiation-induced damage in human cells. Mol Biol Cell 1997;8:1013–23. · DOI
- Jin P, Gu Y, Morgan DO. Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J Cell Biol 1996;134:963–70. · DOI · Paper page
- Poon RY, Chau MS, Yamashita K, Hunter T. The role of Cdc2 feedback loop control in the DNA damage checkpoint in mammalian cells. Cancer Res 1997;57:5168–78.
- Workman JL, Kingston RE. Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem 1998;67:545–79. · DOI · Paper page
- Hansen JC, Tse C, Wolffe AP. Structure and function of the core histone N-termini: more than meets the eye. Biochemistry 1998;37:17637–41. · DOI · Paper page
- Zachos G, Rainey MD, Gillespie DA. Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J 2003;22:713–23. · DOI · Paper page
- Chen Z, Xiao Z, Chen J, et al. Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol Cancer Ther 2003;2:543–8.
- Clump DA, Qazi IH, Sudol M, Flynn DC. c-Yes response to growth factor activation. Growth Factors 2005;23:263–72. · DOI
Cited by
The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/b978-0-12-380888-2.00003-0 · Cited by 1,276
DNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051
Huang, M., & Weiss, W. A. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014415 · Cited by 647
ATM and ATR as therapeutic targets in cancer
Weber, A. M., & Ryan, A. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 635
ATM Mutations in Cancer: Therapeutic Implications
Choi, M., Kipps, T., & Kurzrock, R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0945 · Cited by 453
Metadata
- Authors
- Blasina, A., Hallin, J., Chen, E., Arango, M. E., Kraynov, E., Register, J., Grant, S., Ninkovic, S., Chen, P., Nichols, T., O'Connor, P., & Anderes, K.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2008-08-01
- Volume
- 7
- Issue
- 8
- Pages
- 2394-2404
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2095986441
- Cited by
- 223
- References
- 3
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. https://app.cochat.ai/papers/10.1158/1535-7163.mct-07-2391
- The paper
- Blasina, A., Hallin, J., Chen, E., Arango, M. E., Kraynov, E., Register, J., Grant, S., Ninkovic, S., Chen, P., Nichols, T., O'Connor, P., & Anderes, K. (2008). Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-07-2391
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.